Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ: CCCC )

1.840 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 1.840
Bid (Size) 1.680 (2)
Ask (Size) 2.940 (2)
Prev. Close 1.840
Today's Range 1.840 - 1.840
52wk Range 1.720 - 10.42
Shares Outstanding 48,797,226
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
C4 Therapeutics Announces Chief Financial Officer Succession
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-71.16%
-71.16%
1 Month
-40.07%
-40.07%
3 Month
-33.09%
-33.09%
6 Month
-40.65%
-40.65%
1 Year
-79.53%
-79.53%

More News

Read More
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Inc. (NASDAQ: CCCC) Highlighted for Surprising Price Action
Via Investor Brand Network
The Latest Analyst Ratings for C4 Therapeutics
Via Benzinga
Looking Into C4 Therapeutics's Return On Capital Employed
Via Benzinga
Expert Ratings for C4 Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Nasdaq Edges Lower Following Fed Minutes; C4 Therapeutics Shares Jump
Via Benzinga
Crude Oil Rises Sharply; Impel Pharmaceuticals Shares Spike Higher
Via Benzinga
C4 Therapeutics Inc. (NASDAQ: CCCC) is One of Wednesday Morning’s Most Active Stocks
Via Investor Brand Network
Dow Drops 150 Points; US Factory Orders Increase 0.3% In May
Via Benzinga
Recap: C4 Therapeutics Q1 Earnings
Via Benzinga
Where C4 Therapeutics Stands With Analysts
Via Benzinga
Looking Into C4 Therapeutics's Return On Capital Employed
Via Benzinga
Why 1847 Holdings Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
C4 Therapeutics Stock Is Surging: What's Going On?
Via Benzinga
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer
From C4 Therapeutics, Inc.
Via GlobeNewswire
Week In Review: Betta Pharma Enters $392 Million Deal For C4 Therapeutics’ NSCLC Drug
Via Talk Markets
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From C4 Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.